title: Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.
abstract: This study aims to investigate clinical significance of topoisomerase 2A (TOP2A) expression and TOP2A gene change in operable invasive breast cancer. This is a retrospective analysis, which includes 256 patients diagnosed as operable invasive breast cancer. All postoperational waxed specimens were subjected to resectioning for staining. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), KI-67, TOP2A expression, and TOP2A gene changes were detected by immunohistochemistry (IHC) and fluorescent in situ hybridization technique (FISH), respectively. Correlation between TOP2A expression and clinicopathological characteristics was also investigated. Effects of TOP2A protein or gene changes on survival rate were detected. Results indicated that 165 were TOP2A positive (64.5 %), and 31 were gene amplification positive (12.1 %). Positive rate of TOP2A expression showed significant correlations with ER, KI-67, and HER-2. The difference of 5-year overall survival (OS) between TOP2A-positive and TOP2A-negative groups did not reach statistical significance (OS: P = 0.321, 85.9 vs. 79.6 %; disease-free survival [DFS]: P = 0.247, 83.3 vs. 75.3 %). Five-year OS in TOP2A amplification group was 68.8 %, which is lower than deficiency and control group (P > 0.05). Subgroup analysis showed no significant differences of OS and DFS either between TOP2A-positive and TOP2A-negative groups or between TOP2A amplification and control group in population of patients with HER-2 amplification, triple negative breast cancer, or hormone-positive breast cancer. In conclusion, positive rate of TOP2A expression correlates significantly with ER, KI-67, and HER-2. However, prognostic significance of either TOP2A expression or TOP2A gene changes in breast cancer and its various subtypes is limited.
authors.affiliation: Department of Breast surgery, Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127 Dongming Road, Zhengzhou, 450008, People's Republic of China.
authors.forename: Jiang-Hua
authors.initials: JH
authors.lastname: Qiao
authors.affiliation: Department of Breast surgery, Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127 Dongming Road, Zhengzhou, 450008, People's Republic of China.
authors.forename: De-Chuang
authors.initials: DC
authors.lastname: Jiao
authors.affiliation: Department of Breast surgery, Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127 Dongming Road, Zhengzhou, 450008, People's Republic of China.
authors.forename: Zhen-Duo
authors.initials: ZD
authors.lastname: Lu
authors.affiliation: China-US (Henan) Hormel Cancer Institute, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, People's Republic of China.
authors.forename: Sen
authors.initials: S
authors.lastname: Yang
authors.affiliation: Department of Breast surgery, Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127 Dongming Road, Zhengzhou, 450008, People's Republic of China. liuzhenzzz@yeah.net.
authors.forename: Zhen-Zhen
authors.initials: ZZ
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000096:biosynthesis* / Q000235:genetics; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D004250:DNA Topoisomerases, Type II / Q000096:biosynthesis* / Q000235:genetics; D004268:DNA-Binding Proteins / Q000096:biosynthesis* / Q000235:genetics; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000235:genetics; D000075223:Poly-ADP-Ribose Binding Proteins; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000235:genetics; D011960:Receptors, Estrogen / Q000096:biosynthesis / Q000235:genetics; D011980:Receptors, Progesterone / Q000096:biosynthesis / Q000235:genetics
chemical_list: D000951:Antigens, Neoplasm; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D000075223:Poly-ADP-Ribose Binding Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human; C000618811:TOP2A protein, human
keywords: Clinical significance; Immunohistochemistry; Operable invasive breast cancer; Situ hybridization technique; Topoisomerase
references.citation: Breast Cancer Res Treat. 2012 Jul;134(2):549-60
references.pmid: 22585231
references.citation: J Transl Med. 2012 Jan 12;10:10
references.pmid: 22240029
references.citation: Appl Immunohistochem Mol Morphol. 2014 Mar;22(3):182-7
references.pmid: 23702653
references.citation: Int J Cancer. 2013 Jan 15;132(2):E58-65
references.pmid: 22915138
references.citation: J Pathol. 2014 Jul;233(3):228-37
references.pmid: 24652535
references.citation: Eur J Gynaecol Oncol. 2011;32(2):156-9
references.pmid: 21614903
references.citation: Ann Oncol. 2013 Sep;24(9):2206-23
references.pmid: 23917950
references.citation: Cancer Res. 2007 Aug 1;67(15):7078-81
references.pmid: 17671173
references.citation: J Clin Pathol. 2014 May;67(5):420-5
references.pmid: 24403186
references.citation: Br J Cancer. 2012 Jan 17;106(2):383-8
references.pmid: 22251968
references.citation: Breast Cancer Res Treat. 2011 Jul;128(1):127-36
references.pmid: 21465170
references.citation: J Transl Med. 2012 Oct 23;10:212
references.pmid: 23092535
references.citation: Med Oncol. 2013 Jun;30(2):545
references.pmid: 23532817
references.citation: Cancer Res. 2010 Nov 15;70(22):8994-9002
references.pmid: 21062978
references.citation: Am J Clin Pathol. 2005 Jun;123(6):889-95
references.pmid: 15899781
references.citation: Am J Pathol. 2011 Apr;178(4):1453-60
references.pmid: 21435434
references.citation: Tumour Biol. 2014 Sep;35(9):8685-90
references.pmid: 24870594
references.citation: Tumour Biol. 2014 Jan;35(1):179-87
references.pmid: 23897556
references.citation: J Natl Cancer Inst. 2009 May 20;101(10):736-50
references.pmid: 19436038
references.citation: Clin Cancer Res. 2010 Apr 15;16(8):2391-401
references.pmid: 20371687
references.citation: Oncologist. 2012;17(10):1246-55
references.pmid: 22871798
references.citation: J Cancer Res Clin Oncol. 2008 Feb;134(2):271-9
references.pmid: 17661082
references.citation: J Natl Cancer Inst. 2009 May 6;101(9):644-50
references.pmid: 19401546
references.citation: Breast Cancer Res Treat. 2006 Aug;98(3):337-42
references.pmid: 16502015